Valeant Pharmaceuticals International, Inc. (TSE:VRX) (NYSE:VRX) Director Schutter Richard Urbain De bought 10,000 shares of the stock in a transaction that occurred on Friday, November 17th. The shares were purchased at an average price of C$14.33 per share, for a total transaction of C$143,300.00.
Valeant Pharmaceuticals International, Inc. (TSE VRX) opened at C$22.68 on Friday. Valeant Pharmaceuticals International, Inc. has a fifty-two week low of C$11.20 and a fifty-two week high of C$23.75.
VRX has been the topic of several research analyst reports. Royal Bank Of Canada decreased their price target on shares of Valeant Pharmaceuticals International to C$22.50 and set a “sector perform” rating on the stock in a research note on Friday, October 20th. TD Securities upgraded shares of Valeant Pharmaceuticals International from a “hold” rating to a “buy” rating and set a C$25.50 price target on the stock in a research note on Wednesday, November 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of C$22.50.
ILLEGAL ACTIVITY NOTICE: “Insider Buying: Valeant Pharmaceuticals International, Inc. (VRX) Director Buys 10,000 Shares of Stock” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://ledgergazette.com/2017/12/08/valeant-pharmaceuticals-international-inc-vrx-director-schutter-richard-urbain-de-acquires-10000-shares.html.
Valeant Pharmaceuticals International Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.